TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have earned an average rating of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $50.00.

A number of research analysts recently weighed in on TGTX shares. Wall Street Zen lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research report on Thursday, January 15th. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. Finally, JPMorgan Chase & Co. reduced their target price on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd.

Institutional Trading of TG Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of TG Therapeutics by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 15,841,002 shares of the biopharmaceutical company’s stock worth $472,220,000 after buying an additional 319,703 shares during the period. State Street Corp grew its position in TG Therapeutics by 4.7% in the fourth quarter. State Street Corp now owns 8,479,999 shares of the biopharmaceutical company’s stock valued at $252,789,000 after acquiring an additional 379,380 shares during the period. Geode Capital Management LLC raised its stake in TG Therapeutics by 6.3% during the second quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock worth $126,033,000 after acquiring an additional 207,890 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in TG Therapeutics by 35.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock worth $61,144,000 after acquiring an additional 531,759 shares in the last quarter. Finally, Congress Asset Management Co. bought a new position in shares of TG Therapeutics during the fourth quarter valued at $57,307,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Up 3.8%

TG Therapeutics stock opened at $27.96 on Wednesday. The firm’s 50 day moving average price is $29.52 and its two-hundred day moving average price is $31.50. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.29 and a current ratio of 4.10. TG Therapeutics has a twelve month low of $25.28 and a twelve month high of $46.48. The firm has a market cap of $4.46 billion, a PE ratio of 10.09 and a beta of 1.87.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.21). The business had revenue of $192.57 million for the quarter, compared to the consensus estimate of $192.15 million. TG Therapeutics had a net margin of 72.56% and a return on equity of 101.12%. TG Therapeutics’s revenue was up 78.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.15 EPS. On average, research analysts predict that TG Therapeutics will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.